A Pathway to Immunotherapeutic Targeting of Multiple Cancer Types

Neuroregulin 1 (NRG1) is an epidermal growth factor that is pathogenically altered in about 1% of solid tumors via fusion with one of many partner genes, resulting in a chimeric protein that drives oncogenesis via the HER2/HER3 pathway. Investigators conducted an industry-sponsored, multicenter, phase 2 trial of zenocutuzumab (Zeno), a bispecific anti-HER2 and anti-HER3 monoclonal antibody, in patients with advanced or metastatic cancer and an NRG1 gene fusion as detected by next-generation DNA or RNA sequencing. Eligible patients had either received prior standard therapy, which could include prior anti-HER2 antibodies or inhibitors, or were not candidates for standard therapy. Zeno infusions were administered intravenously once every 2 we…